Notable LOEs through 2028

2023		2024		2025		2026		2027		2028	
Company	Product ('22 Sales)	Company	Product ('23 Sales)	Company	Product ('24 Sales)	Company	Product ('25 Sales)	Company	Product ('26 Sales)	Company	Product ('27 Sales)
abbvie	Humira ($21B)	REGENERON	Eylea ($10B)	AstraZeneca	Soliris ($2.7B)	NOVARTIS	Entresto ($7B)	Pfizer	Eliquis ($15B)	MERCK	Keytruda ($30B)
Johnson & Johnson	Stelara ($10B)	AstraZeneca	Brilinta ($1.4B)	Bristol Myers Squibb	Yervoy ($3B)	EXELIXIS / IPSEN Innovation for patient care	Cabometyx ($1B)	abbvie / J&J	Imbruvica ($12B)	Bristol Myers Squibb	Opdivo ($13B)
Jazz Pharmaceuticals	Xyrem ($1B)	J&J / BAYER	Xarelto ($3B)	Pfizer	Xeljanz ($2B)	Bristol Myers Squibb	Pomalyst ($2.5B)	Pfizer	Ibrance ($9B)	AMGEN	Otezla ($3B)
Biogen	Tysabri ($1.9B)	novo nordisk	Victoza ($1.3B)	AMGEN	Prolia / Xjeva ($6B)	MERCK	Januvia / Janumet ($1B)	Lilly	Trulicity ($8B)	GSK	Tivicay ($4.5B)
sunovion	Latuda ($2B)					Roche	Perjeta ($5.5B)				
NOVARTIS	Gilenya ($1.6B)										
Takeda	Vyvanse ($3.4B)										
Total 'At-Risk' Revenue:	**~$41B**		**~$16B**		**~$14B**		**~$17B**		**~$44B**		**~$50B**

Andrew Pannu @andrewpannu